The USPTO has announced the COVID-19 Prioritized Examination Pilot Program to incentivize prompt research into treatment of this pandemic. The program will benefit small and micro entities by allowing them to file for prioritized examination without the typical fees. To qualify for this program, the claims of the application must cover a product or process that is subject to FDA approval for use in the prevention and/or treatment of COVID-19. The USPTO aims to reach final disposition of applications to this program within six months, if the applicant responds promptly to USPTO communications. WHIPgroup attorneys have significant experience in products and processes subject to FDA approval, including medical devices and chemical compositions. We are ready and able to help you take advantage of this program.
Jasmine Gratton is completing her LL.M in Intellectual Property and Information Technology Law at Fordham University School of Law. She has an LL.B. from University of Bristol Law School in England, and completed her thesis [Read More…]
By Ryan Newell The USPTO has extended the expiration date for the Fast-Track Appeals Pilot Program (F-TAPP) through July 2, 2022. F-TAPP was established in July 2020 on a temporary basis, to provide for the [Read More…]
Whitmyer IP Group filed a Complaint in the District of Delaware on behalf of its clients Nicholas Harmon and With Light, Inc., formerly Verilux, Inc. The Complaint stems from a commercial transaction where Verilux’s assets [Read More…]